ClinicalTrials.gg
RecruitingNCT07707024Updated Nov 10, 2026

Intraoperative Neuromonitoring of Sacral Reflexes to Predict Post Operative Function in Patients Undergoing Sacrectomy for Pelvic Bone Malignancy or Patients Undergoing Spinal Procedures Without Sacral Root Involvement

An interventional study of Intraoperative Nerve Monitoring and Surgical Procedure in Bone Neoplasm and Metastatic Malignant Neoplasm in the Bone, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Diagnostic

Updated Nov 10, 2026Now RecruitingSite recruiting status changedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial tests how well monitoring the sacral reflexes during surgery (intraoperatively) works to predict the post operative function for patients undergoing removal of the lowest part of the spine (sacrectomy) for pelvic bone cancers or patients undergoing spinal procedures. These surgical procedures can lead to damage to sacral root nerves which can result in impairment to the lower extremities, bowel, bladder, and sexual function. Intraoperative monitoring of sacral reflexes can provide objective, real-time information about pelvic nerve function during surgery. This can aid surgical decision-making and help surgeons better prepare patients to understand the changes that may have occurred to their function as a result of surgery. Intraoperative neuromonitoring may work well to predict postoperative function in patients undergoing sacrectomy for pelvic bone malignancy or patients undergoing spinal procedures.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the feasibility of acquiring analyzable sacral reflex neuromonitoring data at baseline and case closure during surgery.

SECONDARY OBJECTIVES:

I. To characterize sacral reflex parameters amplitude, latency, waveform morphology, and Nerveana Power Index (NPI) at baseline under standardized intraoperative neuromonitoring conditions in patients undergoing spinal procedures without sacral nerve root involvement and patients undergoing sacrectomy.

II. To describe intraoperative changes in sacral reflex parameters from baseline to end-of-case during standardized intraoperative neuromonitoring in patients undergoing sacrectomy.

III. To characterize the relative contribution of individual sacral nerve roots to sacral reflex responses during intraoperative stimulation in patients undergoing sacrectomy.

IV. To characterize longitudinal changes in postoperative functional outcomes in patients undergoing sacrectomy.

EXPLORATORY OBJECTIVES:

I. To explore the association between intraoperative sacral reflex changes and postoperative functional outcomes in patients undergoing sacrectomy.

II. To explore the association between sacrifice of higher- versus lower-contributing sacral nerve roots and postoperative functional outcomes in patients undergoing sacrectomy.

OUTLINE:

Patients undergo neuromonitoring of the sacral reflexes at predefined time points during standard of care surgery.

After completion of study treatment, patients are followed up at 21 days, 6 weeks and 3, 6 and 12 months.

02

Conditions studied

  • Bone Neoplasm
  • Metastatic Malignant Neoplasm in the Bone

Browse trials for

03

In context

Bone Neoplasms

258 studies on the registry are indexed under Bone Neoplasms; 68 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 163 interventional studies indexed under Bone Neoplasms.

Browse Bone Neoplasms studies →

Lead sponsor

City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative.

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Age: ≥ 18 years
  • Ability to complete study questionnaires
  • Willingness to comply with all study procedures, including postoperative patient-reported outcome (PRO) assessments
  • Undergoing surgery at City of Hope involving either:

    • Complete or partial sacrectomy for primary or bone tumors, or
    • Thoracolumbar intervention in which the sacral roots are not exposed or manipulated (reference cohort)

Exclusion criteria

Exclusion Criteria:

  • Prior sacrectomy or prior surgery resulting in complete sacral nerve transection
  • For thoracolumbar cohort patients, prior diagnosis or patient report of bowel or bladder dysfunction
  • Cognitive or psychiatric conditions preventing reliable completion of PRO instruments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Diagnostic (Intraoperative neuromonitoring)

    Patients undergo neuromonitoring of the sacral reflexes at predefined time points during standard of care surgery.

    Procedure: Intraoperative Nerve Monitoring · Procedure: Surgical Procedure · Other: Survey Administration

Interventions

  • ProcedureIntraoperative Nerve Monitoring

    Undergo intraoperative neuromonitoring

    Also known as: Intraoperative Neuromonitoring, Intraoperative Neurophysiological Monitoring, IONM

  • ProcedureSurgical Procedure

    Undergo standard of care surgery

    Also known as: Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Reproducible and interpretable bulbocavernosus reflex (BCR) and external urethral sphincter (EUS) reflex responses (feasibility)

    Reproducible is defined as the ability to elicit a reflex response on repeated stimulation with consistent waveform presence and morphology at a given timepoint. Interpretable is defined as a recorded reflex response that is distinguishable from background noise and artifact and permits determination of response presence or absence and measurement of latency and amplitude. A two-sided 95% Clopper-Pearson confidence interval will be provided as a measure of precision.

    Time frame: From baseline, Up to 1 year

Secondary outcomes

  1. Distribution of BCR reflex parameters

    Amplitude, latency, frequency distribution, etc, measured via intraoperative neuromonitoring (IONM). ), Analyses will first be conducted separately within thoracolumber and sacrectomy patient groups. Descriptive statistics will be reported for BCR for each group. Next, to compare the mean values between the two groups, t-test or Mann-Whitney U-test will be implemented depending on the distribution of these parameters. Additionally, within the sacrectomy group, the changes of these parameters from baseline to the end-of-case will be assessed either through paired t-test or Wilcoxon's signed rank test, depending on the distribution of each parameter.

    Time frame: From baseline, Up to 1 year

  2. Distribution of EUS reflex parameters

    Amplitude, latency, frequency distribution, etc, measured via IONM. Analyses will first be conducted separately within thoracolumber and sacrectomy patient groups. Descriptive statistics will be reported for EUS for each group. Next, to compare the mean values between the two groups, t-test or Mann-Whitney U-test will be implemented depending on the distribution of these parameters. Additionally, within the sacrectomy group, the changes of these parameters from baseline to the end-of-case will be assessed either through paired t-test or Wilcoxon's signed rank test, depending on the distribution of each parameter.

    Time frame: From baseline, Up to 1 year

  3. Change in BCR reflex parameters

    Analyses will first be conducted separately within thoracolumber and sacrectomy patient groups. Descriptive statistics will be reported for BCR for each group. Next, to compare the mean values between the two groups, t-test or Mann-Whitney U-test will be implemented depending on the distribution of these parameters. Additionally, within the sacrectomy group, the changes of these parameters from baseline to the end-of-case will be assessed either through paired t-test or Wilcoxon's signed rank test, depending on the distribution of each parameter.

    Time frame: From baseline, Up to 1 year

  4. Change in EUS reflex parameters

    Analyses will first be conducted separately within thoracolumber and sacrectomy patient groups. Descriptive statistics will be reported for EUS for each group. Next, to compare the mean values between the two groups, t-test or Mann-Whitney U-test will be implemented depending on the distribution of these parameters. Additionally, within the sacrectomy group, the changes of these parameters from baseline to the end-of-case will be assessed either through paired t-test or Wilcoxon's signed rank test, depending on the distribution of each parameter.

    Time frame: From baseline, Up to 1 year

  5. Relative contribution of individual right sacral nerve roots to BCR amplitude

    Amplitudes among sacrectomy patients will be descriptively reported.

    Time frame: During intraoperative stimulation, Up to Day 21

  6. Relative contribution of individual left sacral nerve roots to BCR amplitude

    Amplitudes among sacrectomy patients will be descriptively reported.

    Time frame: During intraoperative stimulation, Up to Day 21

  7. Relative contribution of individual right sacral nerve roots to EUS amplitude

    Amplitudes among sacrectomy patients will be descriptively reported.

    Time frame: During intraoperative stimulation, Up to Day 21

  8. Relative contribution of individual left sacral nerve roots to EUS amplitude

    Amplitudes among sacrectomy patients will be descriptively reported.

    Time frame: During intraoperative stimulation, Up to Day 21

  9. Bowel function scores

    Assessed by Memorial Sloan Kettering Bowel Function Instrument. Will be described by graphs and descriptive statistics at each time point.

    Time frame: From baseline, Up to 1 year

  10. Bladder function scores

    Assessed by International Consultation on Incontinence Questionnaire. Will be described by graphs and descriptive statistics at each time point.

    Time frame: From baseline, up to 1 year

  11. Sexual function scores

    Assessed by Female Sexual Function Index (female patients only) and International Index of Erectile Function (male patients only). Will be described by graphs and descriptive statistics at each time point.

    Time frame: From baseline, up to 1 year

  12. Lower extremity function

    Assessed by Toronto Extremity Salvage Score for the Lower Extremity. Will be described by graphs and descriptive statistics at each time point.

    Time frame: From baseline, up to 1 year

  13. Quality of life

    Assessed by Functional Assessment of Cancer Therapy-General. Will be described by graphs and descriptive statistics at each time point.

    Time frame: From baseline, up to 1 year

  14. Postoperative urologic function

    Assessed by post-void residual (PVR) or cystometry. Will be described by graphs and descriptive statistics at each time point.

    Time frame: From baseline, up to 1 year

07

Study locations

1 of 1 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
City of Hope Medical Center is now Recruiting
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    City of Hope Medical Center is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07707024
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jan 10, 2027 (estimated)
Primary completion
Jun 10, 2029 (estimated)
Completion
Jun 10, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Alana M Munger
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion